20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Johnson and Johnson (NYSE: JNJ), through its Janssen Pharmaceutical NV unit, has entered into a deal with the African Vaccine Acquisition Trust that could order an additional 180 million doses of COVID-19 shot for a combined total of 400 million doses through 2022.
- JNJ will initially supply up to 220 million doses of the COVID-19 vaccine to the African Union's 55 member states from the third quarter of 2021.
- "We need to immunize at least 60% of our population in order to get rid of the virus from our continent. The J&J agreement enables us to move towards achieving this target," said John Nkengasong, director of the Africa Centers for Disease Control and Prevention.
- Last year in December, J&J said it and the GAVI vaccine alliance expected to enter into a deal that would provide up to 500 million doses of the company's vaccine to the COVAX program through 2022.
- Johnson & Johnson has established a global manufacturing and supply network for its COVID-19 vaccine, collaborating with nine partners across four continents, including Aspen Pharmacare in South Africa.
- Price Action: JNJ shares are trading 0.7% lower at $163.78 in the premarket on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!